Government-Owned Inventions; Availability for Licensing, 43501-43502 [E6-12338]

Download as PDF rwilkins on PROD1PC63 with NOTICES Federal Register / Vol. 71, No. 147 / Tuesday, August 1, 2006 / Notices focus. Previous efforts have consisted of a more limited approach focusing training at a local/regional level. Amount: The anticipated award amount of $1.8 million will be distributed among the 4 or 5 most highly ranked (by objective review) applicants from the existing 19 BTCDP awardees. Awards will average $360,000. Project Period: The period of support is from September 30, 2006, to August 31, 2007, and will align with the existing budget period. Justification for the Exception to Competition: Open competition applications for the BTCDP program were received and reviewed by an objective review panel in the summer of FY 2005, at which time BTCDP’s local and regional training plans, curriculum and evaluation strategies were reviewed and approved. A total of 74 Continuing Education applications were reviewed and 50 applications were approved. Nineteen projects were funded after careful review from a strongly competitive pool of applicants, emerging as the strongest entities with proven experience and track records to expand their accomplishments to a nationwide target of healthcare providers. Since that time, the awardees have continued to use Federal funds to align their training with the National Preparedness Goal and to deliver training consistent with HRSA’s goals. BTCDP funded programs are uniquely suited to participate in this geographic expansion based upon their authorship and mastery of tested curriculum. BTCDP awardees have been awarded funds specifically to develop training strategies for all healthcare professionals. Their experiences have made them uniquely aware of potential pitfalls to be overcome in developing and testing a national training plan and have the expertise to respond to such barriers as they arise. Since the inception of the program in FY 2003, BTCDP awardees have been responsible for the training of 225,000 healthcare providers on a locality-by-locality basis and stand ultimately poised to deploy and evaluate national training strategies. BTCDP awardees are highly regarded academic institutions which have dedicated staff and infrastructure to create quality training opportunities for healthcare providers. Curriculum created with BTCDP dollars has already been approved by the academic institutions from which they emanate and has already secured the approval of healthcare professional continuing education accreditation bodies. Awardees possess the building blocks of the infrastructure necessary to VerDate Aug<31>2005 20:04 Jul 31, 2006 Jkt 208001 efficiently test a national training system, and they have the knowledge and experience necessary to ensure the efficient use of funds for healthcare preparedness training. The BTCDP is the only Federal program solely committed to the preparedness training of healthcare providers. As such, BTCDP awardees share curriculum, accomplishments and lessons learned through an established network on a regular basis, a network vital to the development of a national plan. Awardees stand uniquely prepared to respond to congressional demand for an efficient and effective national training strategy within the fiscal and time constraints of this supplement. This supplement is the first step in meeting this demand through the efficient use of proven curriculum by experienced trainers on a national basis. FOR FURTHER INFORMATION CONTACT: For further information, please contact Terri Spear, Chief, Emergency Training Branch, 5600 Fishers Lane, Room 13– 103, Rockville, Maryland 20857. E-mail: tspear@hrsa.gov. Dated: July 25, 2006. Elizabeth M. Duke, Administrator. [FR Doc. E6–12267 Filed 7–31–06; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 43501 be required to receive copies of the patent applications. Complement Regulatory Gene Variants as Predictive Tests for Age-Related Macular Degeneration (AMD) Description of Technology: Agerelated macular degeneration (AMD) is a complex multigenic disorder that affects the central region of the retina (macula) and is the leading cause of legal blindness in developed countries. Age, lifestyle (e.g. smoking, diet) and genetic predisposition are major risk factors for AMD and 1.75 million adults over 40 are affected by advanced AMD in the United States with a further 7 million considered to be at risk (defined by the presence of large retinal deposits or drusen, which are the hallmark of this disease). A variety of immuneassociated molecules including immunoglobulins, complement components, activators and regulators, etc. are associated with drusen and evidence suggests that AMD, like other age-related diseases such as Alzheimer’s disease and atherosclerosis, involves a major inflammatory component. Several disease-susceptibility genes have been identified in family studies of macular degeneration and in patient cohorts by several groups including NIH researchers and their collaborators, and variants in the factor H gene (CFH)), a major inhibitor of the alternative complement pathway, have been associated with the risk for developing AMD. NIH researchers and their collaborators have now extended this work to two other regulatory genes of this pathway, Factor B (BF) and complement component 2 (C2). These genes were screened for genetic variation in two independent cohorts comprised of ~900 AMD cases and ~400 matched controls. Haplotype analyses revealed a significant common risk haplotype (H1) and two protective haplotypes (H7 and H10). Combined analysis of the C2/BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the cases and 56% of the controls (Nature Genetics (2006) 38, 458). This suggests that these variants can be used as predictive genetic tests in combination with other potential risk factors. Available for licensing are methods for identifying a subject at increased risk for developing AMD by determining the presence of protective genotypes at either the BF/C2 locus and at the CFH locus. Microarrays and kits are also provided. The complex and polygenic nature of AMD suggests that the protective and risk haplotypes claimed E:\FR\FM\01AUN1.SGM 01AUN1 43502 Federal Register / Vol. 71, No. 147 / Tuesday, August 1, 2006 / Notices here can be of great value not only to companies targeting Macular Degeneration but perhaps more broadly to those involved in complementmediated inflammatory disorders. Inventors: Michael Dean (NCI), Bert Gold (NCI) et al. Patent Status: U.S. Provisional Application No. 60/772,989 filed 13 Feb 2006 (HHS Reference No. E–042–2006/ 0–US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Susan Carson, D.Phil.; 301/435–5020; carsonsu@mail.nih.gov. Collaborative Research Opportunity: The NCI Laboratory of Genomic Diversity is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize functional or genetic tests on complement genes and proteins. Please contact Kathleen Higinbotham at 301/846–5465 for more information. Place: National Institutes of Health, 6100 Executive Boulevard, Room 5B01, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892, (301) 453–6911. hopmann@mail.nih.gov. Dated: July 24, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–12338 Filed 7–31–06; 8:45 am] National Institutes of Health BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. rwilkins on PROD1PC63 with NOTICES Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Time Sensitive Review. Date: August 16, 2006. Time: 11 a.m. to 1 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Meenaxi Hiremath, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301–402–7964, mh392g@nih.gov. Name of Committee: National Institutes of Child Health and Human Development Special Emphasis Panel, Communication of People with Mental Retardation. Date: August 15, 2006. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. VerDate Aug<31>2005 20:04 Jul 31, 2006 Jkt 208001 (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: July 25, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–6606 Filed 7–31–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES (Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: July 26, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–6607 Filed 7–31–06; 8:45 am] BILLING CODE 4140–01–M National Institute on Drug Abuse; Notice of Closed Meetings DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institutes of Health Name of Committee: National Institute on Drug Abuse Special Emphasis Panel, Pathway to Independence Award. Date: August 3, 2006. Time: 1 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, gm145a@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 National Institute on Drug Abuse; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting to the National Advisory Council on Drug Abuse. The meeting will be open to the public as indicated below, with attendance limited to space available. individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council on Drug Abuse. Date: September 19–20, 2006. Close: September 19, 2006, 3 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\01AUN1.SGM 01AUN1

Agencies

[Federal Register Volume 71, Number 147 (Tuesday, August 1, 2006)]
[Notices]
[Pages 43501-43502]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-12338]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Complement Regulatory Gene Variants as Predictive Tests for Age-Related 
Macular Degeneration (AMD)

    Description of Technology: Age-related macular degeneration (AMD) 
is a complex multigenic disorder that affects the central region of the 
retina (macula) and is the leading cause of legal blindness in 
developed countries. Age, lifestyle (e.g. smoking, diet) and genetic 
predisposition are major risk factors for AMD and 1.75 million adults 
over 40 are affected by advanced AMD in the United States with a 
further 7 million considered to be at risk (defined by the presence of 
large retinal deposits or drusen, which are the hallmark of this 
disease). A variety of immune-associated molecules including 
immunoglobulins, complement components, activators and regulators, etc. 
are associated with drusen and evidence suggests that AMD, like other 
age-related diseases such as Alzheimer's disease and atherosclerosis, 
involves a major inflammatory component. Several disease-susceptibility 
genes have been identified in family studies of macular degeneration 
and in patient cohorts by several groups including NIH researchers and 
their collaborators, and variants in the factor H gene (CFH)), a major 
inhibitor of the alternative complement pathway, have been associated 
with the risk for developing AMD.
    NIH researchers and their collaborators have now extended this work 
to two other regulatory genes of this pathway, Factor B (BF) and 
complement component 2 (C2). These genes were screened for genetic 
variation in two independent cohorts comprised of ~900 AMD cases and 
~400 matched controls. Haplotype analyses revealed a significant common 
risk haplotype (H1) and two protective haplotypes (H7 and H10). 
Combined analysis of the C2/BF haplotypes and CFH variants shows that 
variation in the two loci can predict the clinical outcome in 74% of 
the cases and 56% of the controls (Nature Genetics (2006) 38, 458). 
This suggests that these variants can be used as predictive genetic 
tests in combination with other potential risk factors.
    Available for licensing are methods for identifying a subject at 
increased risk for developing AMD by determining the presence of 
protective genotypes at either the BF/C2 locus and at the CFH locus. 
Microarrays and kits are also provided. The complex and polygenic 
nature of AMD suggests that the protective and risk haplotypes claimed

[[Page 43502]]

here can be of great value not only to companies targeting Macular 
Degeneration but perhaps more broadly to those involved in complement-
mediated inflammatory disorders.
    Inventors: Michael Dean (NCI), Bert Gold (NCI) et al.
    Patent Status: U.S. Provisional Application No. 60/772,989 filed 13 
Feb 2006 (HHS Reference No. E-042-2006/0-US-01).
    Licensing Status: Available for non-exclusive or exclusive 
licensing.
    Licensing Contact: Susan Carson, D.Phil.; 301/435-5020; 
carsonsu@mail.nih.gov.
    Collaborative Research Opportunity: The NCI Laboratory of Genomic 
Diversity is seeking statements of capability or interest from parties 
interested in collaborative research to further develop, evaluate, or 
commercialize functional or genetic tests on complement genes and 
proteins. Please contact Kathleen Higinbotham at 301/846-5465 for more 
information.

    Dated: July 24, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E6-12338 Filed 7-31-06; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.